vs
Axon Enterprise（AXON）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Axon Enterprise的季度营收约是Royalty Pharma plc的1.3倍（$796.7M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 0.3%，领先34.1%），Axon Enterprise同比增速更快（38.9% vs 4.8%），过去两年Axon Enterprise的营收复合增速更高（31.5% vs 4.6%）
Axon Enterprise是总部位于美国亚利桑那州斯科茨代尔的企业，面向军队、执法部门及民用市场开发各类武器装备与相关技术产品，业务覆盖公共安全、国防及民用消费等多个领域，为不同用户群体提供适配的产品解决方案。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
AXON vs RPRX — 直观对比
营收规模更大
AXON
是对方的1.3倍
$622.0M
营收增速更快
AXON
高出34.2%
4.8%
净利率更高
RPRX
高出34.1%
0.3%
两年增速更快
AXON
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $796.7M | $622.0M |
| 净利润 | $2.7M | $214.2M |
| 毛利率 | 57.9% | — |
| 营业利润率 | -6.3% | 62.4% |
| 净利率 | 0.3% | 34.4% |
| 营收同比 | 38.9% | 4.8% |
| 净利润同比 | -98.0% | 2.9% |
| 每股收益（稀释后） | $0.02 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXONRPRX
| Q4 25 | $796.7M | $622.0M | ||
| Q3 25 | $710.6M | $609.3M | ||
| Q2 25 | $668.5M | $578.7M | ||
| Q1 25 | $603.6M | $568.2M | ||
| Q4 24 | $573.4M | $593.6M | ||
| Q3 24 | $544.3M | $564.7M | ||
| Q2 24 | $504.1M | $537.3M | ||
| Q1 24 | $460.7M | $568.0M |
净利润AXONRPRX
| Q4 25 | $2.7M | $214.2M | ||
| Q3 25 | $-2.2M | $288.2M | ||
| Q2 25 | $36.1M | $30.2M | ||
| Q1 25 | $88.0M | $238.3M | ||
| Q4 24 | $136.0M | $208.2M | ||
| Q3 24 | $67.0M | $544.0M | ||
| Q2 24 | $40.8M | $102.0M | ||
| Q1 24 | $133.2M | $4.8M |
毛利率AXONRPRX
| Q4 25 | 57.9% | — | ||
| Q3 25 | 60.1% | — | ||
| Q2 25 | 60.4% | — | ||
| Q1 25 | 60.6% | — | ||
| Q4 24 | 60.5% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 60.3% | — | ||
| Q1 24 | 56.4% | — |
营业利润率AXONRPRX
| Q4 25 | -6.3% | 62.4% | ||
| Q3 25 | -0.3% | 70.1% | ||
| Q2 25 | -0.2% | 36.3% | ||
| Q1 25 | -1.5% | 94.0% | ||
| Q4 24 | -2.6% | 60.9% | ||
| Q3 24 | 4.4% | — | ||
| Q2 24 | 6.5% | 50.2% | ||
| Q1 24 | 3.5% | -13.0% |
净利率AXONRPRX
| Q4 25 | 0.3% | 34.4% | ||
| Q3 25 | -0.3% | 47.3% | ||
| Q2 25 | 5.4% | 5.2% | ||
| Q1 25 | 14.6% | 41.9% | ||
| Q4 24 | 23.7% | 35.1% | ||
| Q3 24 | 12.3% | 96.3% | ||
| Q2 24 | 8.1% | 19.0% | ||
| Q1 24 | 28.9% | 0.8% |
每股收益（稀释后）AXONRPRX
| Q4 25 | $0.02 | $0.49 | ||
| Q3 25 | $-0.03 | $0.67 | ||
| Q2 25 | $0.44 | $0.07 | ||
| Q1 25 | $1.08 | $0.55 | ||
| Q4 24 | $1.68 | $0.46 | ||
| Q3 24 | $0.86 | $1.21 | ||
| Q2 24 | $0.53 | $0.23 | ||
| Q1 24 | $1.73 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $618.7M |
| 总债务越低越好 | $1.8B | $9.0B |
| 股东权益账面价值 | $3.2B | $9.7B |
| 总资产 | $7.0B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.56× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资AXONRPRX
| Q4 25 | $1.7B | $618.7M | ||
| Q3 25 | $2.4B | $938.9M | ||
| Q2 25 | $2.1B | $631.9M | ||
| Q1 25 | $2.2B | $1.1B | ||
| Q4 24 | $788.1M | $929.0M | ||
| Q3 24 | $1.0B | $950.1M | ||
| Q2 24 | $968.9M | $1.8B | ||
| Q1 24 | $964.1M | $843.0M |
总债务AXONRPRX
| Q4 25 | $1.8B | $9.0B | ||
| Q3 25 | $2.0B | $8.9B | ||
| Q2 25 | $2.0B | $8.0B | ||
| Q1 25 | $2.0B | $7.6B | ||
| Q4 24 | $680.3M | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益AXONRPRX
| Q4 25 | $3.2B | $9.7B | ||
| Q3 25 | $3.0B | $9.6B | ||
| Q2 25 | $2.7B | $9.5B | ||
| Q1 25 | $2.6B | $9.8B | ||
| Q4 24 | $2.3B | $10.3B | ||
| Q3 24 | $2.1B | $10.3B | ||
| Q2 24 | $1.9B | $9.8B | ||
| Q1 24 | $1.8B | $9.9B |
总资产AXONRPRX
| Q4 25 | $7.0B | $19.6B | ||
| Q3 25 | $6.7B | $19.3B | ||
| Q2 25 | $6.2B | $18.3B | ||
| Q1 25 | $6.1B | $17.6B | ||
| Q4 24 | $4.5B | $18.2B | ||
| Q3 24 | $4.0B | $18.0B | ||
| Q2 24 | $3.7B | $17.7B | ||
| Q1 24 | $3.6B | $16.1B |
负债/权益比AXONRPRX
| Q4 25 | 0.56× | 0.92× | ||
| Q3 25 | 0.66× | 0.93× | ||
| Q2 25 | 0.73× | 0.84× | ||
| Q1 25 | 0.79× | 0.78× | ||
| Q4 24 | 0.29× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $217.2M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $155.4M | — |
| 自由现金流率自由现金流/营收 | 19.5% | — |
| 资本支出强度资本支出/营收 | 7.8% | — |
| 现金转化率经营现金流/净利润 | 79.14× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $75.1M | — |
8季度趋势，按日历期对齐
经营现金流AXONRPRX
| Q4 25 | $217.2M | $827.1M | ||
| Q3 25 | $60.0M | $702.6M | ||
| Q2 25 | $-91.7M | $364.0M | ||
| Q1 25 | $25.8M | $596.1M | ||
| Q4 24 | $250.2M | $742.5M | ||
| Q3 24 | $91.3M | $703.6M | ||
| Q2 24 | $82.8M | $658.2M | ||
| Q1 24 | $-15.9M | $664.6M |
自由现金流AXONRPRX
| Q4 25 | $155.4M | — | ||
| Q3 25 | $33.4M | — | ||
| Q2 25 | $-114.7M | — | ||
| Q1 25 | $932.0K | — | ||
| Q4 24 | $225.4M | — | ||
| Q3 24 | $64.8M | — | ||
| Q2 24 | $71.4M | — | ||
| Q1 24 | $-32.1M | — |
自由现金流率AXONRPRX
| Q4 25 | 19.5% | — | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | -17.2% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 39.3% | — | ||
| Q3 24 | 11.9% | — | ||
| Q2 24 | 14.2% | — | ||
| Q1 24 | -7.0% | — |
资本支出强度AXONRPRX
| Q4 25 | 7.8% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 3.4% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 4.9% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | 3.5% | — |
现金转化率AXONRPRX
| Q4 25 | 79.14× | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | -2.54× | 12.06× | ||
| Q1 25 | 0.29× | 2.50× | ||
| Q4 24 | 1.84× | 3.57× | ||
| Q3 24 | 1.36× | 1.29× | ||
| Q2 24 | 2.03× | 6.45× | ||
| Q1 24 | -0.12× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXON
| Software And Sensors Segment | $342.5M | 43% |
| TASER Devices Professional | $264.2M | 33% |
| Personal Sensors | $109.1M | 14% |
| Platform Solutions | $80.9M | 10% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
